Although this agent was not found to contribute significantly to the reduction of the incidence of cardiovascular disease by elevated HDL-C level in recent trials [25], whether a CETP inhibitor can improve the prognosis of sepsis in humans is worth investigating, as the decline of the HDL-C level is more pathologically striking and appears to be combined with decreased functional metrics in sepsis [23, 30, 31]. Here, CETP is linked to cardiovascular disorder.